Skip to main content

CASE REPORT article

Front. Med.
Sec. Nephrology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1519604
This article is part of the Research Topic Innovative Therapeutic Strategies for Chronic Kidney Disease: From Molecular Mechanisms to Clinical Practice View all 3 articles

Comprehensive Management Application of Sulodexide on Proteinuria: 2 Case Reports

Provisionally accepted
Li Zhou Li Zhou Wenge Li Wenge Li *
  • Beijing China-Japan Friendship Hospital, Beijing, China

The final, formatted version of the article will be published soon.

    Proteinuria is an important sign of kidney function decline and one of the common clinical manifestations in patients with chronic kidney disease and diabetic kidney disease, which are often accompanied by a gradual decline in kidney function. Therefore, effective management of proteinuria is of great significance for delaying the progression of kidney disease and protecting kidney function. Sulodexide is a mixture of fast-moving heparin and dermatan sulfate with anticoagulant, thrombolytic, anticardiovascular, lipid-lowering, and renal-protective effects. It has potential application value in the comprehensive management of proteinuria. This study reported two different chronic disease cases to explore the comprehensive management application of sulodexide in patients with long-term poor proteinuria control. Case 1 is a 45-year-old male with type 2 diabetes mellitus and hypertension accompanied by persistent proteinuria and intermittent edema in both legs. Case 2 is a 52-year-old female with chronic nephritis and rheumatoid arthritis accompanied by persistent proteinuria and edema in both legs. Two patients showed a decrease in urinary protein levels and stable control of the remaining signs of disease after the addition of sulodexide to their comprehensive treatment regimens, indicating that sulodexide plays an important role in the comprehensive management of proteinuria.

    Keywords: Proteinuria, Chronic Kidney Disease, cdiabetic kidney disease, chronic diseases, Sulodexide

    Received: 30 Oct 2024; Accepted: 15 Jan 2025.

    Copyright: © 2025 Zhou and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wenge Li, Beijing China-Japan Friendship Hospital, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.